HIGHLIGHTS
- who: Paul J. Hampel from the (UNIVERSITY) have published the research work: Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib, in the Journal: (JOURNAL) of 11/08/2022
- what: The authors focus on outcomes after progression on ibrutinib in a large cohort of patients with CLL, reporting survival estimates with varied treatments, line-of-therapy settings, and patterns of progression. The authors report on a meaningfully large cohort of nearly 150 patients showing a median overall survival of 25.5 months from Blood Cancer Journal 12:124 5 the time . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.